|
[23] KHACHIGIAN L M, VARCOE R L, SUORANTA T, et al. Gene Therapeutic Strategies for Peripheral Artery Disease and New Opportunities Provided by Adeno-Associated Virus Vectors [J]. Arterioscler Thromb Vasc Biol, 2023, 43(6): 836-51.DOI:10.1161/atvbaha.122.318902. [24] MORISHITA R, AOKI M, HASHIYA N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease [J]. Hypertension, 2004, 44(2): 203-9.DOI:10.1161/01.HYP.0000136394.08900.ed. [25] POWELL R J, SIMONS M, MENDELSOHN F O, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia [J]. Circulation, 2008, 118(1): 58-65.DOI:10.1161/circulationaha.107.727347. [26] POWELL R J, GOODNEY P, MENDELSOHN F O, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial [J]. J Vasc Surg, 2010, 52(6): 1525-30.DOI:10.1016/j.jvs.2010.07.044. [27] SHIGEMATSU H, YASUDA K, IWAI T, et al. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia [J]. Gene Ther, 2010, 17(9): 1152-61.DOI:10.1038/gt.2010.51. [28] PYUN W B, HAHN W, KIM D S, et al. Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia [J]. Gene Ther, 2010, 17(12): 1442-52.DOI:10.1038/gt.2010.101. [29] GU Y, ZHANG J, GUO L, et al. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia [J]. J Gene Med, 2011, 13(11): 602-10.DOI:10.1002/jgm.1614. [30] GU Y, CUI S, WANG Q, et al. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia [J]. Mol Ther, 2019, 27(12): 2158-65.DOI:10.1016/j.ymthe.2019.10.017. [31] DI X, LIU C, NI L, et al. Rationale and design for the study of recombinant human hepatocyte growth factor plasmid in the treatment of patients with chronic limb-threatening ischemia (HOPE CLTI): Randomized, placebo-controlled, double-blind, phase III clinical trials [J]. Am Heart J, 2022, 254: 88-101.DOI:10.1016/j.ahj.2022.08.007. [32] CUI S, GUO L, LI X, et al. Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia [J]. Eur J Vasc Endovasc Surg, 2015, 50(4): 494-501.DOI:10.1016/j.ejvs.2015.05.007. [33] GU Y, CUI S, LIU C, et al. pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcer: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial [J]. Hum Gene Ther, 2021, 32(15-16): 839-49.DOI:10.1089/hum.2020.290. [34] CREAGER M A, OLIN J W, BELCH J J, et al. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication [J]. Circulation, 2011, 124(16): 1765-73.DOI:10.1161/circulationaha.110.009407. [35] SHISHEHBOR M H, RUNDBACK J, BUNTE M, et al. SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial [J]. Vasc Med, 2019, 24(3): 200-7.DOI:10.1177/1358863x18817610. [36] BATES D O, MAVROU A, QIU Y, et al. Detection of VEGF-A(xxx)b isoforms in human tissues [J]. PLoS One, 2013, 8(7): e68399.DOI:10.1371/journal.pone.0068399. [37] GANTA V C, CHOI M, KUTATELADZE A, et al. VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease [J]. Circ Res, 2017, 120(2): 282-95.DOI:10.1161/circresaha.116.309516. [38] FINDLEY C M, MITCHELL R G, DUSCHA B D, et al. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease [J]. J Am Coll Cardiol, 2008, 52(5): 387-93.DOI:10.1016/j.jacc.2008.02.045. [39] CHOKSY S, POCKLEY A G, WAJEH Y E, et al. VEGF and VEGF receptor expression in human chronic critical limb ischaemia [J]. Eur J Vasc Endovasc Surg, 2004, 28(6): 660-9.DOI:10.1016/j.ejvs.2004.09.001. [40] BRANDãO D, COSTA C, CANEDO A, et al. Endogenous vascular endothelial growth factor and angiopoietin-2 expression in critical limb ischemia [J]. Int Angiol, 2011, 30(1): 25-34 [41] PALMER-KAZEN U, WARIARO D, LUO F, et al. Vascular endothelial cell growth factor and fibroblast growth factor 2 expression in patients with critical limb ischemia [J]. J Vasc Surg, 2004, 39(3): 621-8.DOI:10.1016/j.jvs.2003.07.006. |
